Vote Scores
Filings read through

Arrowhead Pharmaceuticals, Inc.: how funds voted at the meeting of 19 Mar 2026

Ticker
ARWR
Meeting
Season
year to 30 June 2026
Filers reporting
519
Ballot items
4

519 filers on Form N-PX reported votes at the Arrowhead Pharmaceuticals, Inc. meeting of 19 Mar 2026. The records fall into 4 ballot items. The page lists them in ballot order: items of the company first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting.

If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.

The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .

The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.

The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.

The page gives records. It gives no investment advice and no advice on how to vote.

Season on this page: year to 30 June 2026. Filings read through . How the figures are made

The ballot

ForAgainstAbstain, withhold or otherAmber tick: the part cast against management

  1. Item 1: Director elections

    7 nominees. 92.6% of the reported votes are for. 33 filers withheld from or voted against at least one nominee.

    2,338 vote records from 168 filers. 3 of the 168 filers that marked the item voted against management.

    • Positions of 45 fund families
    • For 44
    • Against 1
    • Against management 1
  2. Item 2: Advisory vote on executive pay (say-on-pay)

    786 vote records from 517 filers. 335 of the 489 filers that marked the item voted against management. 28 filers gave no management mark.

    • Positions of 48 fund families
    • For 9
    • Against 39
    • Against management 38
  3. Item 3: Audit-related items (auditor ratification)

    334 vote records from 168 filers. 2 of the 168 filers that marked the item voted against management.

    • Positions of 45 fund families
    • For 45
  4. Item 4: COMPENSATION: management items

    The company's items in this category are shown together, because filers word and number them differently.

    345 vote records from 173 filers. 5 of the 173 filers that marked the item voted against management.

    • Positions of 45 fund families
    • For 45

Positions of the fund families

A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.

KeyForAgainstAbstain or withholdSplit or no voteAgainst management

Fund families at Arrowhead Pharmaceuticals, Inc., meeting of 19 Mar 2026Families in name order. "Abstain" includes withhold. "Split" includes no vote. "No report" means that no filer of the family listed the item.
Fund family2. Say-on-pay3. Auditor
AllianceBernsteinAgainst, against managementNo report
AllspringAgainst, against managementFor
American CenturyForFor
BairdForNo report
BlackRock and iSharesAgainst, against managementFor
BNY MellonAgainst, against managementFor
Brighthouse FundsAgainstFor
Charles SchwabAgainst, against managementFor
Columbia ThreadneedleAgainst, against managementFor
DimensionalAgainst, against managementFor
DWSAgainst, against managementFor
EquitableAgainst, against managementFor
Federated HermesForFor
FidelityAgainst, against managementFor
First TrustAgainst, against managementFor
Franklin TempletonAgainst, against managementFor
Global XAgainst, against managementFor
Goldman SachsForFor
Guggenheim and RydexAgainst, against managementFor
InvescoAgainst, against managementFor
J.P. MorganAgainst, against managementFor
Jackson National fundsAgainst, against managementFor
Janus HendersonAgainst, against managementFor
John Hancock and ManulifeAgainst, against managementFor
Lincoln FinancialForFor
Lord AbbettAgainst, against managementFor
MassMutualAgainst, against managementFor
Morgan Stanley, Eaton Vance and CalvertForFor
NationwideAgainst, against managementFor
Natixis and Loomis SaylesAgainst, against managementNo report
Neuberger BermanAgainst, against managementFor
Northern Trust and FlexSharesForFor
Nuveen and TIAAForFor
Pacific Life fundsAgainst, against managementFor
PGIM and PrudentialAgainst, against managementFor
PrincipalAgainst, against managementFor
ProShares and ProFundsAgainst, against managementFor
Russell InvestmentsAgainst, against managementFor
SEIAgainst, against managementFor
State Street and SPDRForFor
T. Rowe PriceAgainst, against managementFor
ThriventAgainst, against managementFor
TransamericaAgainst, against managementFor
VanguardAgainst, against managementFor
Victory CapitalAgainst, against managementFor
VirtusAgainst, against managementFor
VoyaAgainst, against managementFor
WisdomTreeAgainst, against managementFor

Questions

How many filers reported votes at the Arrowhead Pharmaceuticals, Inc. meeting?
519 Form N-PX filers reported votes at the meeting of 19 Mar 2026. On say-on-pay, 335 of 489 filers that marked the item voted against management (68.5%).
Is this the result of the meeting?
No. The page counts the filers that report on Form N-PX, and the shares they reported. Arrowhead Pharmaceuticals, Inc. reports the result of a vote on Form 8-K.
Why does the page show counts only for director elections?
A director record names the nominee. This site has no page and no row about a person. For director elections it keeps the number of nominees and the split of votes.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Arrowhead Pharmaceuticals, Inc. with a meeting date within three days of 19 Mar 2026. A proposal title is the most common wording among filers. Where a wording can name a person, the SEC category is shown. The filers wrote the filings. Filings read through .